Proove is the only company presenting data on how genetic tests can improve the efficiency of pain medication and treatment - Brian Meshkin, CEO, Proove Biosciences
Irvine, CA (PRWEB) April 15, 2014
Proove Biosciences, the leader in Personalized Pain Medicine testing services, exhibited and presented three abstracts last week at the American Society of Interventional Pain Physicians’ (ASIPP) 16th annual meeting, and received first place for its research on how a proprietary algorithm identifies workers’ compensation claims that are at risk for extending beyond one-year.
The abstract, Predictive Risk of Injury Complications Enduring Over one Year Using Genetic Predisposition (P.R.I.C.E.), was presented by Proove’s Medical Director for Pain and Addiction, Daniel Schwarz, MD, MROC. In this study of 272 patients, a PRICE score of 3 was able to predict claims extending beyond 1 year with an accuracy of 52% positive predictive value (+PPV) and a sensitivity of 88% and specificity of 92%.
The PRICE Study suggests that by performing Proove’s proprietary genetic analysis on every workers compensation claim that extends beyond 30-days, a clinician and insurer can possibly identify patients who would require more effective therapy early in the episode of care to resolve the injury earlier and end the claim before a year. This could help avoid the dramatic cost escalations that occur in claims extending beyond one year, and reduce costs by 57%, providing a much greater return to the worker’s compensation carrier and employer.
“Proove is the only company presenting data on how genetic tests can improve the efficiency of pain medication and treatment,” stated Brian Meshkin, CEO and founder of Proove Biosciences. “The ASIPP Annual Meeting is a premier industry event, and we are honored that our 3 study posters were chosen to be among the top 20, one was chosen to be presented for oral presentation, and in that competition, our PRICE study was awarded 1st overall. To be honored among industry leaders like Boston Scientific, Medtronic, St. Jude, and Johnson & Johnson, I’m so proud of our team and collaborative researchers. In the emerging field of pain medicine genetics, Proove continues to display our industry leadership with unique testing and published research showing outcomes data, placing a huge distance between Proove and other labs who market run-of-the-mill drug metabolism genetic testing.”
ASIPP’s 16th annual meeting was held the weekend of April 4th in New Orleans. Proove Biosciences Medical Advisory Board members, Dr. Andrea Trescot, and Sandy Silverman, are active leaders in ASIPP. The PRICE study abstract was presented on Saturday, April 5th.
About the American Society of Interventional Pain Physicians
The American Society of Interventional Pain Physicians is a not-for-profit organization representing interventional pain physicians across the country. The organization has been growing rapidly since 1998 and has had a substantial impact on the practice of interventional pain medicine.
About Proove Biosciences
Proove Biosciences is the leading Personalized Pain Medicine laboratory that provides proprietary genetic testing services to help physicians improve outcomes for patients and contain costs for insurers. With offices in Southern California and the Baltimore-Washington metropolitan area, the Company is the research leader investigating and publishing data on the genetics of pain medicine with clinical research sites across the United States. Physicians use Proove Biosciences testing to improve pain medicine selection, dosing, and evaluation of medications they prescribe. From a simple cheek swab collected in the office, Proove performs proprietary genetic tests in its CLIA-certified laboratory to identify patients at risk for misuse of prescription pain medications and evaluate their metabolism of medications. For more information, please visit http://www.proovebio.com or call toll free 855-PROOVE-BIO (855-776-6832).